立他司特滴眼液在健康研究参与者体内的药代动力学特征及安全性的I期临床研究
[Translation] Phase I clinical study on the pharmacokinetic characteristics and safety of lifalast eye drops in healthy study participants
评价立他司特滴眼液在中国健康研究参与者中单次给药后的血浆、泪液药代动力学特征及安全性
[Translation] To evaluate the plasma and tear pharmacokinetic characteristics and safety of lifalast eye drops after a single dose in participants of the Chinese Health Study
立他司特滴眼液用于治疗干眼症的有效性和安全性的多中心、随机、双盲、安慰剂平行对照Ⅲ期临床研究
[Translation] A multi-center, randomized, double-blind, placebo-controlled phase III clinical study on the efficacy and safety of Litalast eye drops in the treatment of dry eye syndrome
[Translation] To evaluate the effectiveness and safety of Ritalast eye drops in patients with dry eye syndrome
硫酸阿托品滴眼液(不同浓度)延缓儿童近视进展的有效性和安全性的随机、双盲、安慰剂对照、多中心Ⅱ/Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II/III clinical trial of the efficacy and safety of atropine sulfate eye drops (different concentrations) in delaying the progression of myopia in children
评价不同浓度的硫酸阿托品滴眼液与安慰剂相比延缓儿童近视进展的疗效
[Translation] To evaluate the efficacy of different concentrations of atropine sulfate eye drops compared with placebo in delaying the progression of myopia in children
100 Clinical Results associated with Nanjing Ruinian Best Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Nanjing Ruinian Best Pharmaceutical Co., Ltd.
100 Deals associated with Nanjing Ruinian Best Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Nanjing Ruinian Best Pharmaceutical Co., Ltd.